Insider Buying: Venture Life Group (LON:VLG) Insider Buys 48,373 Shares of Stock

Venture Life Group plc (LON:VLG) insider Paul McGreevy bought 48,373 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of GBX 62 per share, for a total transaction of £29,991.26.

Paul McGreevy also recently made the following trade(s):

• On Wednesday, June 3rd, Paul McGreevy purchased 15,663 shares of Venture Life Group stock. The stock was acquired at an average cost of GBX 64 per share, with a total value of £10,024.32.
• On Wednesday, June 3rd, Paul McGreevy purchased 8,066 shares of Venture Life Group stock. The shares were acquired at an average price of GBX 62 per share, for a total transaction of £5,000.92.
• On Wednesday, June 3rd, Paul McGreevy acquired 8,105 shares of Venture Life Group stock. The stock was acquired at an average cost of GBX 62 per share, for a total transaction of £5,025.10.

Venture Life Group Stock Up 2.7%

Venture Life Group stock opened at GBX 66.75 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 4.71 and a quick ratio of 1.48. The stock has a market capitalization of £81.32 million, a PE ratio of 15.27, a price-to-earnings-growth ratio of 5.67 and a beta of 0.24. The business has a 50 day simple moving average of GBX 61.09 and a 200-day simple moving average of GBX 64.11. Venture Life Group plc has a 12 month low of GBX 49 and a 12 month high of GBX 72.

Venture Life Group (LON:VLG) last announced its earnings results on Tuesday, March 31st. The company reported GBX (1.49) earnings per share (EPS) for the quarter. Venture Life Group had a net margin of 17.42% and a return on equity of 7.82%. The business had revenue of GBX 3,517 million for the quarter. On average, analysts anticipate that Venture Life Group plc will post 6.1391542 EPS for the current fiscal year.

Venture Life Group Company Profile

Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.

Headquartered in the UK, the Group’s product portfolio includes Balance Activ in the area of women’s intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.